Valeant's Allergan bid gets hostile as Ackman makes a play for board control

Save

Valeant CEO J. Michael Pearson and the company's largest shareholder, Bill Ackman, have been trying to propel Allergan's board toward deal negotiations ever since they announced their first unsolicited bid back in April. And now, they're adding a little extra incentive.